What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Ribavirin
- Virus
His main research concerns Internal medicine, Hepatitis C, Hepatitis C virus, Ribavirin and Immunology.
The various areas that Mark S. Sulkowski examines in his Internal medicine study include Gastroenterology, Surgery, Viral load and Sofosbuvir.
His Hepatitis C study integrates concerns from other disciplines, such as Hepatitis B, Interleukin 28B, Rapid Virologic Response, Coinfection and Cohort.
Mark S. Sulkowski combines subjects such as Liver disease and Hepatocellular carcinoma with his study of Hepatitis C virus.
His work on Adverse effect expands to the thematically related Ribavirin.
His Immunology research is multidisciplinary, relying on both Clinical trial and Ritonavir.
His most cited work include:
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. (3072 citations)
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection (1943 citations)
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection (1080 citations)
What are the main themes of his work throughout his whole career to date?
Mark S. Sulkowski mainly focuses on Internal medicine, Ribavirin, Gastroenterology, Hepatitis C and Hepatitis C virus.
His studies deal with areas such as Chronic hepatitis, Surgery and Sofosbuvir as well as Internal medicine.
His studies in Ribavirin integrate themes in fields like Interferon and Adverse effect.
His work in the fields of Gastroenterology, such as Cirrhosis, overlaps with other areas such as In patient.
His Hepatitis C study results in a more complete grasp of Immunology.
The concepts of his Hepatitis C virus study are interwoven with issues in Coinfection and Viral load.
He most often published in these fields:
- Internal medicine (62.60%)
- Ribavirin (40.24%)
- Gastroenterology (39.43%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (62.60%)
- Hepatitis C virus (36.99%)
- Hepatitis C (37.20%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Hepatitis C virus, Hepatitis C, Gastroenterology and Virology.
His work deals with themes such as Coinfection and Ribavirin, Sofosbuvir, which intersect with Internal medicine.
His Ribavirin research includes themes of Regimen, Adverse effect and NS5A.
His Hepatitis C virus research integrates issues from Direct acting, Viral load, Drug and Intensive care medicine.
His research on Hepatitis C also deals with topics like
-
Care Continuum together with Public health,
-
Randomized controlled trial which intersects with area such as Nursing and Clinical trial.
His Gastroenterology study also includes fields such as
-
Hepatitis B most often made with reference to Liver biopsy,
-
Ombitasvir, which have a strong connection to Ombitasvir/paritaprevir/ritonavir.
Between 2017 and 2021, his most popular works were:
- Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus–Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial (149 citations)
- The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United States: A National Registry Study. (97 citations)
- Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study (72 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Virus
- Disease
His primary scientific interests are in Internal medicine, Gastroenterology, Hepatitis C virus, Hepatitis C and Sofosbuvir.
Mark S. Sulkowski works mostly in the field of Internal medicine, limiting it down to topics relating to Paritaprevir and, in certain cases, Kidney disease.
Mark S. Sulkowski has researched Gastroenterology in several fields, including Interquartile range, Liver biopsy, Regimen, Adverse effect and Ribavirin.
His Hepatitis C virus research is within the category of Virology.
His research in Hepatitis C intersects with topics in Tailored treatment, Liver transplantation, Poisson regression, Hepatitis and Care Continuum.
Mark S. Sulkowski interconnects Ledipasvir, Cirrhosis and Randomized controlled trial in the investigation of issues within Sofosbuvir.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
